Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Hematologic Malignancies
•
Leukemia
•
Hematology
How do you manage a myocardial infarction secondary to hyperleukocytosis and leukostasis related to AML?
Related Questions
What is the role of post-transplant FLT3 inhibition given the results of BMT-CTN 1506 (MORPHO)?
Does the presence of asparaginase antibodies on Granger Genetics testing indicate need to switch asparaginase formulations?
Do complex cytogenetics have any therapeutic or prognostic relevance in CLL?
What are your top takeaways in Hematologic Malignancies from ASCO 2023?
Would you offer intensive CNS prophylaxis to Ph negative B-ALL patients who have possible mandibular nerve involvement on MRI face?
How would you treat an LGL leukemia patient who has been refractory to treatments with cyclosporine, MTX, and cyclophosphamide?
What is your approach to re-challenging BTK inhibitors for a patient who has had intolerance to several different agents?
Would you re challenge a CLL patient, who had good response to Zanubrutinib but contracted cryptococcal pneumonia, with another TKI?
How do you dose arsenic in a super-morbid person (>500 lbs) with APML?
What induction would you choose for a healthy 65 year old with prior chemo/RT for H&N cancer 2 years ago, now with FLT3-ITD+ (0.25) and inv(16) AML?
